A useful hormone replacement therapy consultation should answer five questions: what problem the treatment is intended to address, which product and route fit that purpose, how your medical history affects the choice, what monitoring is needed, and who will manage it over time. “Should I take hormones?” is usually too broad to produce a useful answer.
Menopausal hormone therapy can help appropriate patients with troublesome symptoms, but systemic therapy, low-dose vaginal treatment, and compounded preparations are different decisions. This guide helps you organize a consultation without choosing a personal prescription. If you are still clarifying the life stage itself, start with perimenopause and menopause assessment.
What are we treating, and what would success look like?
Identify the symptom that most affects your life. Is it frequent hot flashes, night sweats that fragment sleep, pain with sex, or something else? Ask whether the proposed therapy is expected to address that particular problem and how long an initial trial should take before its usefulness can be judged.
The Menopause Society’s patient guidance distinguishes systemic therapy from low-dose vaginal treatment. Systemic treatment circulates through the body and can address temperature symptoms. Local vaginal products principally address symptoms affecting vaginal and urinary tissues. A person can need a conversation about local symptoms even if they do not want or need systemic therapy.
Turn the goal into something observable: fewer sweat-related awakenings, greater comfort during sex, or less interruption at work. This is more meaningful than a promised hormone target or an assurance that treatment will restore a younger version of your body. Also identify symptoms that will need separate evaluation if they persist.
How do my age, timing, and history change the discussion?
The benefit-risk balance is influenced by age, time since menopause, formulation, route, and personal health. The Menopause Society describes a generally more favorable balance for appropriate candidates younger than 60 or within 10 years of menopause onset who have no contraindications. This is a framework for discussion, not an automatic eligibility test or a guarantee of safety.
Bring information about blood clots, stroke, heart disease, unexplained bleeding, liver disease, cancer, migraine, and the medicines you use. Family history and personal history are not interchangeable; give details about the relative, diagnosis, and age where known. A clinician can explain which factors alter the choice, require another opinion, or make a particular therapy unsuitable.
Early ovarian insufficiency or surgical menopause may require a different discussion from starting systemic treatment many years after natural menopause. If your history is complex, ask which specialist should be involved before a prescription is started abroad or during a short residential program.
Do I need estrogen alone or protection for the uterine lining?
For people who retain a uterus, systemic estrogen generally requires an appropriate progestogen regimen to protect the endometrium. The NHS treatment guide explains why estrogen-only and combined treatment are used in different circumstances. Low-dose local vaginal estrogen is a separate situation; do not transfer instructions from systemic treatment without checking the exact product.
Tell the prescriber which gynecologic operations you have had. A remembered phrase such as “partial hysterectomy” may be insufficient, so an operative report can be useful. If an intrauterine system is part of the plan, confirm its specific product, insertion date, and intended role. Devices are not all interchangeable for contraception and endometrial protection.
Ask whether treatment is sequential or continuous and what that means for bleeding. Make sure the written instructions cover every component. Having an estrogen prescription without understanding the companion medicine creates an avoidable gap, particularly when different clinics or pharmacies supply the products.
Why choose a tablet, patch, gel, spray, or local product?
Route is a clinical decision as well as a convenience decision. NICE recommends discussing differences between oral and transdermal treatment, estrogen-only and combined regimens, hormone types, dose, and duration. A patch is not simply a tablet delivered more luxuriously, and one brand’s instructions do not necessarily apply to another.
Ask about the reason for the recommended route in your circumstances. Then discuss everyday use: skin sensitivity, remembering tablets, travel, bathing, storage, application, and accidental transfer of topical medicines to other people. Follow the product-specific instructions rather than advice intended for a different preparation.
Clarify what to do after a missed application or a detached patch and who can answer those questions. A treatment that is theoretically suitable but difficult to use consistently may need a different practical arrangement. Do not double a dose or improvise a schedule without the relevant prescribing advice.
What do the 2026 US label changes mean?
In February 2026, the FDA announced approved labeling changes for six menopausal hormone therapy products. Statements about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning for those products. The agency described these as the first batch of changes following its wider review.
A change to the most prominent warning is not a declaration that all formulations have identical effects or that personal risk assessment is unnecessary. It also does not establish that hormone therapy extends life or prevents every disease associated with aging. Ask the clinician to use the current complete label for the exact product, alongside current guidance and your history.
If you have an older leaflet or have heard a sweeping claim online, bring it to the appointment. The productive question is which information has changed for your proposed medicine and which precautions still apply. Care in another country may involve different authorized products and labeling.
Is the prescription for symptoms or for general disease prevention?
These are different purposes. The USPSTF recommendation on primary prevention advises against systemic hormone therapy solely to prevent chronic conditions in otherwise asymptomatic postmenopausal people. Its scope does not cover treating menopausal symptoms and does not apply to premature ovarian insufficiency or surgical menopause.
That distinction prevents two common misunderstandings: a prevention recommendation does not mean all symptom treatment is inappropriate, and symptom benefit does not prove a general longevity benefit. Ask the prescriber to name the indication rather than grouping symptom relief, bone health, brain health, and anti-aging together.
If fracture prevention is a concern, discuss your actual risk and the available approaches. The guide to bone density testing explains why age, history, and the result’s ability to change management matter more than adding a scan to every package.
What does “bioidentical” tell me about the product?
The term describes a molecular relationship; it does not by itself establish regulatory approval, manufacturing consistency, or superior safety. Some approved hormone products are described as bioidentical. A custom-compounded preparation is a different category.
ACOG recommends FDA-approved menopausal hormone therapies over compounded preparations when approved options are available. The Endocrine Society’s position statement also explains concerns about unsupported claims and dosing based on hormone tests.
Ask for the generic ingredient, product name, route, regulatory status, and reason for choosing it. If compounding is proposed, ask what specific need cannot be met by an approved product and what quality controls apply. A bespoke formula and a costly saliva panel do not demonstrate that the treatment is more individualized in a clinically useful sense.
How will bleeding, side effects, and response be reviewed?
NICE updated its advice about unscheduled bleeding during systemic therapy in April 2026. Ask for instructions matched to the regimen, your bleeding history, and when treatment was started or changed. Do not interpret a general statement that early bleeding can occur as permission to ignore any amount or pattern indefinitely.
Separate routine review from problems that need earlier contact. Record when a symptom started, whether the dose changed, and what other medicines were taken. If bleeding is heavy, persistent, newly appears after an established pattern, or is accompanied by concerning symptoms, contact the responsible clinician for individualized advice.
At review, discuss benefit, adverse effects, adherence, and whether the original goal still applies. Ask whether testing is needed for a specific reason. Repeating broad hormone panels is not a substitute for checking whether treatment helps and remains appropriate.
What if I prefer another option?
There are symptom-specific alternatives. Our guide to nonhormonal menopause support explains why a medicine for hot flashes, CBT for symptom coping, and treatment for chronic insomnia address different needs. Having a choice should not mean being directed toward an unverified supplement package.
If your main concern is discomfort, urinary symptoms, or sexual function, describe it directly. The sexual and pelvic health guide can help you prepare. Persistent symptoms deserve a focused assessment rather than repeated changes to systemic treatment without a clear explanation.
Do I still need contraception?
Menopausal hormone therapy does not prevent pregnancy. If pregnancy is possible, discuss contraception separately, including whether your existing method affects bleeding or the interpretation of symptoms. Do not assume a treatment described as progesterone, or a device recommended by another clinic, covers both purposes. A clear plan should identify which product serves which role and when its suitability needs to be reviewed.
Who owns the prescription after I leave?
Before starting treatment during travel, confirm who will supply refills, interpret side effects, review bleeding, and coordinate with your usual clinician. Ask whether the prescribed product is available where you live and whether your home clinician has agreed to continue it. A discharge letter does not automatically create that agreement.
Keep a complete medication list with generic names, formulation, instructions, start date, and contact details. Record the next review date and the changes that should trigger earlier contact. The consultation has done its job when you understand both the reason for treatment and how it will be managed after the initial decision.